Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • The Bottom by Sanda Strugar Wins Bronze in A’ Jewelry Awards
    The Bottom by Sanda Strugar Wins Bronze in A’ Jewelry Awards Business
  • War Day 166: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych  & #Feygin
    War Day 166: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • Overseas Schools Advisory Council Meeting, Thursday, January 26, 2023
    Overseas Schools Advisory Council Meeting, Thursday, January 26, 2023 World News
  • David Callaghan, VP Sales for SPI Software Named to Board of Canadian Resort & Travel Association
    David Callaghan, VP Sales for SPI Software Named to Board of Canadian Resort & Travel Association Business
  • ReoStar Signs LOI With L. Myers Associates for Acquisition
    ReoStar Signs LOI With L. Myers Associates for Acquisition Business
  • Successful 2022 Milestones Support Value of Gb Sciences’ AI-Enabled Drug Discovery Platform
    Successful 2022 Milestones Support Value of Gb Sciences’ AI-Enabled Drug Discovery Platform Business
  • Independent Contract Nurses: Tax Season is Here
    Independent Contract Nurses: Tax Season is Here Business
  • FAA Announces Notice of Limited Waiver of Slot Usage Requirement for Summer 2023
    FAA Announces Notice of Limited Waiver of Slot Usage Requirement for Summer 2023 Aviation
TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma

TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma

Posted on March 15, 2023 By NewsEditor
TTC Oncology LLC Signs a Collaboration Agreement With Lantern PharmaTTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma

EDINA, Minn., March 15, 2023 (Newswire.com) - TTC Oncology ("TTC" or the "Company") announced the signing of a Collaboration Agreement (the "Agreement") with Lantern Pharma Inc. ("LTRN") to expand the clinical development of the TTC drug candidate TTC-352. The Phase-2 ready candidate, TTC-352, is an orally available small molecule being developed as a treatment for patients with metastatic estrogen receptor-positive ("ER+") breast cancer who have failed two or more prior therapies. TTC-352 is a first-in-class selective human ER partial agonist (ShERPA) that in metastatic disease causes ER to induce breast cancer cell death.

The collaboration will be powered by Lantern's artificial intelligence (AI) platform, RADR®, and its 25+ billion oncology-focused data points, 200+ advanced ML algorithms, as well as its four multi-faceted AI drug discovery and development modules. The initial aims of the collaboration will be to 1) identify biomarker or gene signatures to power potential patient selection for an upcoming TTC-352 Phase 2 clinical trial, 2) further characterize TTC-352's mechanism of action, and 3) discover additional treatment indications for TTC-352.

Breast cancer afflicts approximately 2.1 million women in the U.S. yearly with the majority of these cases being ER+, in which ER promotes tumor growth. Patients with ER+ breast cancer are initially treated with endocrine therapy, which blocks the tumorigenic actions of ER. Unfortunately, almost half of all patients who undergo endocrine therapy develop endocrine-resistant metastatic disease and will need chemotherapy as a last resort. TTC-352 provides an alternative approach without the toxicity associated with chemotherapy. 

Under the terms of the collaboration, Lantern Pharma is receiving an exclusive right to license TTC-352, including any collaboration intellectual property (IP), during an exclusive option period. Additionally, Lantern and TTC will each participate in upfront, milestone, and royalty payments in the event a third party licenses IP resulting from the collaboration. No further financial details were disclosed.

About Lantern Pharma

Lantern Pharma ("LTRN") is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® AI and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes. For more information, please visit the company's website at www.lanternpharma.com.

About TTC Oncology LLC

TTC Oncology is an emerging biotechnology company founded in 2015. TTC Oncology's mission is to develop and bring to market a novel, small-molecule therapy, TTC-352, to address the unmet needs of breast cancer patients. TTC has a license from the University of Illinois at Chicago covering the therapy. https://ttconcology.com/ TTC is currently raising funds to complete Phase II studies. 

Contact Information:
Joe Cunningham
CFO
[email protected]
6129911778


Original Source: TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma

The post TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma first appeared on Social Gov.

Business

Post navigation

Previous Post: Diverge Health Launched to Build Upon a Decade of Experience Serving Underserved Patients in New York
Next Post: Augmenta acquired by CNH Industrial

Related Posts

  • Aquarius Home Services Makes 2022 Another Gold Year in the Star Tribune’s Minnesota Best
    Aquarius Home Services Makes 2022 Another Gold Year in the Star Tribune’s Minnesota Best Business
  • ReoStar Signs LOI With L. Myers Associates for Acquisition
    ReoStar Signs LOI With L. Myers Associates for Acquisition Business
  • Expected to Grow at a CAGR of 5.8% from 2018 to 2025 , Claims AMR
    Expected to Grow at a CAGR of 5.8% from 2018 to 2025 , Claims AMR Business
  • Sugar Free Mints Market Trend to Reflect Tremendous Growth Potential With A Highest CAGR by 2031
    Sugar Free Mints Market Trend to Reflect Tremendous Growth Potential With A Highest CAGR by 2031 Business
  • SellersFi Backs Fusion5 in Launching Florida-based Production Center for Cost-Effective Laptops and Tablets
    SellersFi Backs Fusion5 in Launching Florida-based Production Center for Cost-Effective Laptops and Tablets Business
  • CHAM Agency Sets New Standards in User Experience
    CHAM Agency Sets New Standards in User Experience Business
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
« Aug    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • INDIAN SUPREME COURT SIT GIVES VANTARA A CLEAN CHIT, CONFIRMS FULL REGULATORY COMPLIANCESeptember 17, 2025
  • A Decade Defined by Financial Fragmentation, Ubiquitous Touchpoints, and the Great Wealth TransferSeptember 17, 2025
  • War in Ukraine, Analytics. Day 1285: Putin, Modi and Xi Meeting in China. Arestovych, Shelest.September 16, 2025
  • Attorney John Williams Joins Missouri Criminal Defense Firm Combs WaterkotteSeptember 16, 2025
  • Amy Shira Teitel, Space Historian and Author, Weighs In on NASA’s Moon Race: Safety Can’t Be SacrificedSeptember 16, 2025
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • ArtVersion Honored With Two Prestigious Awards by the Academy of Interactive & Visual Arts
    ArtVersion Honored With Two Prestigious Awards by the Academy of Interactive & Visual Arts Business
  • Pulse Technology CEO Chip Miceli named to national magazine ENX “Difference Maker” list
    Pulse Technology CEO Chip Miceli named to national magazine ENX “Difference Maker” list Business
  • War Day 132: war diaries w/Advisor to Ukraine President, Intel Officer @Alexey Arestovych  & #Feygin
    War Day 132: war diaries w/Advisor to Ukraine President, Intel Officer @Alexey Arestovych & #Feygin World News
  • Day 514: Putin’s Escalations
    Day 514: Putin’s Escalations World News
  • Marrakech Treasures Unveils New Website and Exclusive Collection
    Marrakech Treasures Unveils New Website and Exclusive Collection Business
  • Experts at Gingerlilly Weigh In on Why Sustainable Fashion Matters
    Experts at Gingerlilly Weigh In on Why Sustainable Fashion Matters Business
  • WAISL launches India’s first Digital Twin-Powered Integrated APOC at Hyderabad Airport
    WAISL launches India’s first Digital Twin-Powered Integrated APOC at Hyderabad Airport Business
  • Cabicash Solutions Inc., D/b/a Ualett, Secures  Million Line of Credit to Accelerate Growth
    Cabicash Solutions Inc., D/b/a Ualett, Secures $50 Million Line of Credit to Accelerate Growth Business
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2023 195 News. All Rights Reserved by Coolaser | Partner of VUGA Enterprises |  Advertising: Get Published

Powered by .